India, Feb. 23 -- Zimbabwe has started rolling out Lenacapavir, the new long-acting injectable HIV-prevention drug, becoming one of the first countries in the world to do so.

Lenacapavir is the first twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV, offering a highly effective, long-acting alternative to daily oral pills. With only two doses per year, experts say it provides a practical option for people who face challenges with adherence, stigma, or limited access to healthcare. It also expands available choices in HIV prevention services.

Seeking to curb worrisome new infections, the roll-out, which took place on February 19 in Epworth - a shanty settlement some 20 km south of the capital Harare - started with 46,000 do...